Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSK41959-2
- Development stage
- Unknown
- Lead developer
- Haisco Pharmaceutical Group
01
Overview
HSK41959-2: sourced facts only. name: "HSK41959-2 is a MTA-cooperative PRMT5 inhibitor, which could selectively inhibits PRMT5 in the present of MTA with IC50 was 0.80 nM." [DOI:10.1158/1538-7445.am2024-4595]; target: "HSK41959-2 is a MTA-cooperative PRMT5 inhibitor, which could selectively inhibits PRMT5 in the present of MTA with IC50 was 0.80 nM." [DOI:10.1158/1538-7445.am2024-4595]; developer: "1Haisco Pharmaceutical Group Co., Ltd., Chengdu, China;" [DOI:10.1158/1538-7445.am2024-4595]; stage: "In the HCT116 MTAP-del xenograft model, daily orally administrated with 25 mpk and 100 mpk HSK41959-2 showed significant tumor growth inhibition, with TGI were 62% and 88%, and PRMT5-dependent SDMA protein inhibition were 89% and 95%, respectively." [DOI:10.1158/1538-7445.am2024-4595]
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on HSK41959-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSK41959-2.